替比夫定治疗慢性乙型肝炎的研究进展  

Recent advancement of telbivudine in the treatment of chronic hepatitis B

作　　者：王海燕[1] 王煜[2] 彭晓明[1] 刘娅[2] 

机构地区：[1]宁夏医科大学,银川750004 [2]宁夏医科大学总医院感染疾病科,银川750004

出　　处：《临床肝胆病杂志》2011年第12期1320-1322,1326,共4页Journal of Clinical Hepatology

基　　金：宁夏自然科学基金(NZ10118)

摘　　要：替比夫定是一种新型的抗HBV作用的核苷类似物,其HBeAg血清学转换率高、起效早,耐药发生率低。了解替比夫定的药理作用,选择合适的病例进行治疗,在治疗过程中及时监测,根据第24周时患者的HBV DNA水平来指导后期的治疗,有助于达到长期抑制HBV的目的。Telbivudine is a novel nucleoside analogue against hepatitis B virus with fast HBeAg seroconversion rate, early viral response and low drug tolerance rate. It is helpful in achieving the long term suppression of HBV by understanding the pharmaeokinetics of Telbivudine, selecting the appropriate patients for treatment, timely monitoring the patients during treatment and guiding post - treatment by the patient＇ s first 24 weeks HBV - DNA levels.

关 键 词：肝炎 乙型 慢性 肝炎病毒 替比夫定 

分 类 号：R512.62[医药卫生—内科学]